Member Info for Elsol

"Many customers going through land and expand in revenue growth built off large 2024 efforts" loud and clear ...my take analogy is a timeline akin to ITX developmental 'storming' 2020- 2023, 'norming' (2024), now 'performing'(2025/26). Thunderbirds are 'go' and investors fail to wait for start of prize giving year 2026+ Sad investor journey if you are impatient bit great one for believing LTHs.

A few folks here are trading in and out of the stock to slim off "small profits" and recycling to other investments then back in and good luck to them. I know this and that's my point but you can decide. Also one instance of dual accounts of one person playing good cop, bad cop. Of course there are high risks doing so but some cunning individuals like the spin angles. That's not helpful during news announcement times and hence some volatility overlay today. But stock fundamentals will deliver as we grow - the business is performing on its new strategy and new inbound investors will benefit as BodR calls out.

I just think we still have overhang of long term investors that wanted to maybe exit or realise some profits earlier. That's it. The issue is investors locked in and with a bit of understandable impatience. That's it. The company is clearly delivering what it says on the tin, albeit 2 yrs later than everyone anticipated. Think carefully investors out there before you press the sell button is my advice until 2026 Q1 or Q2. If you do sell I think you will miss out of some profit by selling up prematurely today.

Just for clarity Surfie, to me it's only dissappointing re: historical SP BUT the sales growth is now pretty amazing and must be in top 5% of spec. chem companies with decent margin trajectory. So my point is the SP will have to correlate upwards as we go through $10m in a few months time and then upwards from there ITX has to get more value accretion in H1 26 as we power towards cashflow breakeven. The fixed costs eventually get overcome as a proportion of revs then are profits flowing...

Dear BRADDERS22 - once again a poster that has 2 single posts "today" since 2020 joining. Never a word before. We have seen this recently - what ever happened to "Arkham", an alter ego of someone no doubt that now has gone into the ether? Desperate for shares no doubt to sell fear and doom on ITX in order to buy in and then sell again in 1 -2 weeks. Im you think its a trade in opportunity and you are right my friend. That's my view on this so caution other readers. If you had a large holding and major loss surely you would have been more vocal and participating in the Q&A submissions to management over the years. Duplicate dormant accounts being used for tactical purposes?

The company has delivered, continues to deliver and will deliver very strong revenue growth - this looks almost certain as at today's date. What's happened in the past is irrelevant. Its a small company with raidly growing visibility with major FMCG and industry suppliers and on cusp of profitability. Its share price is rediculously low and share vols at this point are low but as mkt shares grows in next few months we surpass $10m sales. Thereafter sky is the limit toward $15m and $20m so the SP has to follow. Its that simple. It's nice to know we diversify portfolio every day and attack new applications, we just need a lumpy one then everything changes in investor sentiments and newbies buy the stock. DYOR

Thx Tony, been super busy without time to dig deep into the Half year detail, but based on this CEO video itx all seems well set for high growth revenues, expanded gross profit ( which guess what) will soonish mean we go cashflow and profit breakeven - not sure why negative reaction - we've now got through the turbulent risk phase of the company development, lots of new clients on boarding and happy company as far as one can tell - spinning lots of plates without dropping anything. It's certainly a v. strong buy at this price for end 25 and H1 26 horizon and share price lift with more inbound news we know is coming.

Smart investor - did you submit your questions,. Apologies I'm in a meeting and can't join the call unfortunately. If not please can someone do so. Thx

Hi Smart are you able to submit your allocated Qs? Thx.

No response as yet AJP

Mine are loaded and locked for Monday - looking forward to it!

Questions have now been sent informally via private email to John & Laura to flag key questions being observed in investor group discussion forums so they can reflect over the weekend. Please all send your formal questions (investor platform) well before Monday. Thanks all, my best, Elsol

NOTE #2 - PLEASE ALSO DELETE YOUR INITIALS!!!

Q8. Regarding CEO recent quote about manufacturing footprint expansion: Does this mean that current plant capacity could become stretched in the next 12/18 months, and is it possible to give some sort of insight as to how big these customer opportunities are likely to be relative to existing key accounts or segment sizes? Related to this, what are the main anticipated funding alternatives should ITX secure a v. large 2026/27 commercial supply agreement and require another plant (e.g. could this be collaboratively equity financed with the said partner(s), another institutional raise or via bank debt or under a specialist asset backed lending?). (ES)

Q9. What sort of timescales are we looking at for the next addition to the Bio-Asterix product range? How has the initial response been to the e-commerce site? (AJP)

Q10. In the last presentation one of the slides showed a picture of a tube of toothpaste, can you advise on the significance of this please? (SI)

Q11. In the last presentation you talked about the current superabsorbent ingredient we have available with comparable market performance, but cost was an issue, can you elaborate on why it is so more costly and are you looking at ways of remedying this (e.g. scale up, production under licence etc)? (AJP)

Q12. You advised there would be regular granular updates on SPARKS progress, thus far we have not heard anything on this, can you advise please? (ELS)

Q13. The new product Zinador 35D, is this now readily available from Croda since currently nothing is showing on their website to show it can be purchased? (SI)

Q14. Can you advise on what impact the following will have on demands for ITX ingredients/Increased revenue streams in 2026: From June 13 to June 20, 2025, 8 new cosmetic ingredients were notified with the China National Medical Products Administration (NMPA). Notification 20250070. (AJP)

Q15. Any updates on sustainable fashion (Wacca)?

Q16. Itaconix was a project partner in a funded grant looking into new Branched Polymers Excipients and Emulsions for Enhanced Drug Delivery - can you advise on this and if there are any potential future commercial advantages to this research or any further progress in this area?

Project Partners: Clinton Health Access Initiative CHAI Itaconix (UK) Limited Medicines Patent Pool https://gow.epsrc.ukri.org/NGBOViewGrant.aspx?GrantRef=EP/R024804/1 (AJP)

Dear all - final Q list below (1-16) with allocation of initials (SI, AJP, ELS, Wacca) for who should submit them on the investor meeting platform (I have randomly allocated some of AJPs across SI/ELS/Wacca):

!!NOTE - please take off the Q1/8 etc before your question in the live submission!!

Q1. Is H2 trading in July and August off to another strong start? (SI)

Q2. Please advise latest breakeven and profit timeline expectations. (AJP)

Q3. Can you advise on where we are as regards staffing and filling of the current positions being advertised please? (ELS)

Q4. In regard to OTC share trading platform, there has not been a trade on this platform since the 28th of Feb 2025, what can be done if anything to raise ITX’s profile and number of trades (no directors trade/purchase since early 2024, will this change?) (AJP)

Q5. Have you considered bringing in a dedicated media/communications team to help showcase the company’s vision, passion and high growth investor opportunity since it could really amplify the impact of your investor messaging and help drive customer expansion? This includes actually doing the presentations formats professionally and focusing the external messaging of the high impact value drivers of ITX solutions. (Wacca)

Q6. The business is booming but the share price doesn’t yet reflect the progress that the company is making. What steps is the company taking to raise its external investor profile with prospective new retail investors and especially in USA/Canada and across Europe? In this context (so far) the ITX share consolidation appears not to have encouraged a significant uptick of US investors thus far – is there a large investor communication strategy needed in US investor channels to raise awareness of ITX as a fantastic investment growth platform? (SI)

Q7. Regarding CEO recent quote: “We have all the capacity we need to meet our needs over the next 12 to 18 or 24 months. That being said we are going to start taking a look at our production footprint, at what it could look like a few years out, based on some very sizeable opportunities in projects in our customer’s pipeline.” Is it possible to give some more insight into which segments of the business are these high growth areas (e.g. paints or adhesives for example)? Are the prospective counter-parties large multinational type entities and which global regions are the primary targets and does this align with an optimal manufacturing footprint for new plant in Europe? (AJP)

Yes, I will send full set to John as heads up for what to expect on the investor call so they can prepare accordingly. Could I ask all providers of questions to submit pre weekend to the question input platform linked to the Web session. Thx all. AJP since you have many, I'm happy to submit some of yours but pls let me know.

Sounds good AJP

Ditto Thordon, hope all going to be better in future. Welcome back to the group.

Must be a size limit issue:

Q8. Regarding CEO recent quote about manufacturing footprint expansion: Does this mean that current plant capacity could become stretched in the next 12/18 months, and is it possible to give some sort of insight as to how big these customer opportunities are likely to be relative to existing key accounts or segment sizes? Related to this, what are the main anticipated funding alternatives should ITX secure a v. large 2026/27 commercial supply agreement and require another plant (e.g. could this be collaboratively equity financed with the said partner(s), another institutional raise or via bank debt or under a specialist asset backed lending?). (ES)

Q9. What sort of timescales are we looking at for the next addition to the Bio-Asterix product range? How has the initial response been to the e-commerce site? (AJP)

Q10. In the last presentation one of the slides showed a picture of a tube of toothpaste, can you advise on the significance of this please? (AJP)

Q11. In the last presentation you talked about the current superabsorbent ingredient we have available with comparable market performance, but cost was an issue, can you elaborate on why it is so more costly and are you looking at ways of remedying this (e.g. scale up, production under licence etc)? (AJP)

Q12. You advised there would be regular granular updates on SPARKS progress, thus far we have not heard anything on this, can you advise please? (AJP)

Q13. The new product Zinador 35D, is this now readily available from Croda since currently nothing is showing on their website to show it can be purchased?

Q14. Can you advise on what impact the following will have on demands for ITX ingredients/Increased revenue streams in 2026: From June 13 to June 20, 2025, 8 new cosmetic ingredients were notified with the China National Medical Products Administration (NMPA). Notification 20250070.

Q15. Any updates on sustainable fashion (AJP).

Q16. Itaconix was a project partner in a funded grant looking into new Branched Polymers Excipients and Emulsions for Enhanced Drug Delivery - can you advise on this and if there are any potential future commercial advantages to this research or any further progress in this area?

Project Partners: Clinton Health Access Initiative CHAI Itaconix (UK) Limited Medicines Patent Pool https://gow.epsrc.ukri.org/NGBOViewGrant.aspx?GrantRef=EP/R024804/1

Here is the list so far - many from AJP so maybe some of the wider team can help to upload a pre-agreed selection across investors via further dialogue here first. Have a look and come back with any other questions or recommended changes:

Q1. Is H2 trading in July and August off to another strong start? (SI)

Q2. Please advise latest breakeven and profit timeline expectations. (AJP)

Q3. Can you advise on where we are as regards staffing and filling of the current positions being advertised please? (AJP)

Q4. In regard to OTC share trading platform, there has not been a trade on this platform since the 28th of Feb 2025, what can be done if anything to raise ITX’s profile and number of trades (no directors trade/purchase since early 2024, will this change?) (AJP)

Q5. Have you considered bringing in a dedicated media/communications team to help showcase the company’s vision, passion and high growth investor opportunity since it could really amplify the impact of your investor messaging and help drive customer expansion? This includes actually doing the presentations formats professionally and focusing the external messaging of the high impact value drivers of ITX solutions. (Wacca)

Q6. The business is booming but the share price doesn’t yet reflect the progress that the company is making. What steps is the company taking to raise its external investor profile with prospective new retail investors and especially in USA/Canada and across Europe? In this context (so far) the ITX share consolidation appears not to have encouraged a significant uptick of US investors thus far – is there a large investor communication strategy needed in US investor channels to raise awareness of ITX as a fantastic investment growth platform? (SI)

Q7. Regarding CEO recent quote: “We have all the capacity we need to meet our needs over the next 12 to 18 or 24 months. That being said we are going to start taking a look at our production footprint, at what it could look like a few years out, based on some very sizeable opportunities in projects in our customer’s pipeline.” Is it possible to give some more insight into which segments of the business are these high growth areas (e.g. paints or adhesives for example)? Are the prospective counter-parties large multinational type entities and which global regions are the primary targets and does this align with an optimal manufacturing footprint for new plant in Europe? (AJP)

Q8. Regarding CEO recent quote about manufacturing footprint expansion: Does this mean that current plant capacity could become stretched in the next 12/18 months, and is it possible to give some sort of insight as to how big these customer opportunities are likely to be relative to existing key accounts or segment sizes? Related to this, what are the main anticipated funding alternatives should ITX secure a v. large 2026/27 commercial supply agreement and require another plant (e.g. could this be collaboratively equity finan

Yes an interesting one! Oil production / development and drilling related?? Halliburton is a large US oil service company. Cement solidification modulator?